183 related articles for article (PubMed ID: 7387856)
21. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.
Robertson JF; Jaeger W; Syzmendera JJ; Selby C; Coleman R; Howell A; Winstanley J; Jonssen PE; Bombardieri E; Sainsbury JR; Gronberg H; Kumpulainen E; Blamey RW
Eur J Cancer; 1999 Jan; 35(1):47-53. PubMed ID: 10211087
[TBL] [Abstract][Full Text] [Related]
22. A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients.
Nicolini A; Carpi A; Di Marco G; Giuliani L; Giordani R; Palla S
Cancer; 1989 May; 63(10):2037-46. PubMed ID: 2702573
[TBL] [Abstract][Full Text] [Related]
23. Comparison between serum levels of carcinoembryonic antigen, sialic acid and phosphohexose isomerase in lung cancer.
Patel PS; Raval GN; Rawal RM; Patel GH; Balar DB; Shah PM; Patel DD
Neoplasma; 1995; 42(5):271-4. PubMed ID: 8552208
[TBL] [Abstract][Full Text] [Related]
24. Lipid bound sialic acid in cancer patients.
Salvagno L; Ferrazzi E; Sileni VC; Maggi S; Tredese F; Bedendo C; Russo MP; Fiorentino MV; Ceriotti G
Tumori; 1985 Apr; 71(2):127-33. PubMed ID: 4002346
[TBL] [Abstract][Full Text] [Related]
25. Serum lipid-bound sialic acid as a tumoral marker in minimal residual tumors.
Musset M; Mathé G; Reizenstein P
Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):17-20. PubMed ID: 2663215
[TBL] [Abstract][Full Text] [Related]
26. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
Gielen F; Dequeker J; Drochmans A; Wildiers J; Merlevede M
Br J Cancer; 1976 Sep; 34(3):279-85. PubMed ID: 974001
[TBL] [Abstract][Full Text] [Related]
27. Significance of serum concentrations of carcinoembryonic antigen, ferritin, and calcitonin in breast cancer.
Bezwoda W; Derman D; Bothwell T; MacPhil P; Levin J; De Moor N
Cancer; 1981 Oct; 48(7):1623-8. PubMed ID: 7284963
[TBL] [Abstract][Full Text] [Related]
28. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
[TBL] [Abstract][Full Text] [Related]
29. [What value should be given to assays of serum ferritin in breast cancers? Correlation with various biological parameters].
Dalifard I; Daver A; Cellier P; Larra F
Sem Hop; 1984 Jan; 60(3):157-62. PubMed ID: 6320439
[TBL] [Abstract][Full Text] [Related]
30. Red blood cell membrane and serum sialic acid in relation to erythrocyte sedimentation rate.
Levinsky H; Rothman G; Lapidot M; Allalouf D
Acta Haematol; 1980; 64(5):276-80. PubMed ID: 6779485
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
32. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
[TBL] [Abstract][Full Text] [Related]
33. The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type.
Agrawal AK; Jelen M; Rudnicki J; Grzebieniak Z; Zyśko D; Kielan W; Słonina J; Marek G
Folia Histochem Cytobiol; 2010 Jan; 48(1):26-9. PubMed ID: 20529812
[TBL] [Abstract][Full Text] [Related]
34. Prospective assessment of the role of five tumour markers in breast cancer.
Robertson JF; Pearson D; Price MR; Selby C; Pearson J; Blamey RW; Howell A
Cancer Immunol Immunother; 1991; 33(6):403-10. PubMed ID: 1878893
[TBL] [Abstract][Full Text] [Related]
35. Carcinoembryonic antigen, ferritin, anionic glycoproteins, and their sialic acid content in advanced colorectal cancer.
Cunietti E; Locatelli E; Vaiani G; Gandini R; Gandini MC; Reggiani A; Monti M
Cancer Detect Prev; 1985; 8(1-2):227-32. PubMed ID: 4064042
[TBL] [Abstract][Full Text] [Related]
36. [Studies into carcino-embryonic antigen (CEA) and enzyme activities of alkaline and acid phosphatase in patients with fibrocystic breast disease (author's transl)].
Opri F; Kirchner H
Zentralbl Gynakol; 1981; 103(10):564-8. PubMed ID: 7269869
[TBL] [Abstract][Full Text] [Related]
37. Serum tumor markers in metastatic breast cancer and course of disease.
Caffier H; Brandau H
Cancer Detect Prev; 1983; 6(4-5):451-7. PubMed ID: 6197167
[TBL] [Abstract][Full Text] [Related]
38. Biochemical markers in human breast cancer.
Coombes RC; Powles TJ; Gazet JC; Ford HT; Sloane JP; Laurence DJ; Neville AM
Lancet; 1977 Jan; 1(8003):132-4. PubMed ID: 64663
[TBL] [Abstract][Full Text] [Related]
39. Relation between raised concentrations of fucose, sialic acid, and acute phase proteins in serum from patients with cancer: choosing suitable serum glycoprotein markers.
Turner GA; Skillen AW; Buamah P; Guthrie D; Welsh J; Harrison J; Kowalski A
J Clin Pathol; 1985 May; 38(5):588-92. PubMed ID: 2582003
[TBL] [Abstract][Full Text] [Related]
40. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
